Q1. Explain factors affecting bioavailability.

This is question 1 (5 marks) from the GTU Bioavailability and Therapeutic Drug Monitoring BP Winter 2019 question paper. Subject code: 2280008.

Q1. Discuss the role of clinical pharmacist in TDM.

This is question 1 (5 marks) from the GTU Bioavailability and Therapeutic Drug Monitoring BP Winter 2019 question paper. Subject code: 2280008.

Q3. Explain HPTLC techniques used in TDM.

This is question 3 (5 marks) from the GTU Bioavailability and Therapeutic Drug Monitoring BP Winter 2019 question paper. Subject code: 2280008.

Bioavailability and Therapeatic Drug Monitoring | B.Pharm Semester 8 Winter 2019 | GTU Papers

Q: Q1. What is Invitro-Invivo correlation studies? Explain it in detail.

This is question 1 (6 marks) from the GTU Bioavailability and Therapeutic Drug Monitoring BP Winter 2019 question paper. Subject code: 2280008.

Q: Q2. Enumerate Immunoassay methods used in TDM. Explain RIA in detail.

This is question 2 (6 marks) from the GTU Bioavailability and Therapeutic Drug Monitoring BP Winter 2019 question paper. Subject code: 2280008.

Q: Q2. Explain collection & storage of body fluid samples.

This is question 2 (5 marks) from the GTU Bioavailability and Therapeutic Drug Monitoring BP Winter 2019 question paper. Subject code: 2280008.

Q: Q2. Write down criteria for selection of methods of TDM.

This is question 2 (5 marks) from the GTU Bioavailability and Therapeutic Drug Monitoring BP Winter 2019 question paper. Subject code: 2280008.

Q: Q3. Define Bioavailability and Bioequivalence. Discuss objectives of BA studies.

This is question 3 (6 marks) from the GTU Bioavailability and Therapeutic Drug Monitoring BP Winter 2019 question paper. Subject code: 2280008.

Q: Q4. Explain study designs and analysis of BA-BE studies.

This is question 4 (6 marks) from the GTU Bioavailability and Therapeutic Drug Monitoring BP Winter 2019 question paper. Subject code: 2280008.

Questions20

What is Invitro-Invivo correlation studies? Explain it in detail.

[6 marks]

Explain factors affecting bioavailability.

[5 marks]

Discuss the role of clinical pharmacist in TDM.

[5 marks]

Enumerate Immunoassay methods used in TDM. Explain RIA in detail.

[6 marks]

Explain collection & storage of body fluid samples.

[5 marks]

Write down criteria for selection of methods of TDM.

[5 marks]

Define Bioavailability and Bioequivalence. Discuss objectives of BA studies.

[6 marks]

Explain methods and parameters of assessing bioavailability.

[5 marks]

Explain HPTLC techniques used in TDM.

[5 marks]

Explain study designs and analysis of BA-BE studies.

[6 marks]

Write down TDM for Gentamycin.

[5 marks]

Write adverse drug reaction & drug interaction of Theophylline.

[5 marks]

Write down TDM for Phenobarbitone.

[6 marks]

Write various problems of interference of biological matrix.

[5 marks]

Write a note on determination of AUC. Q. 6 (a) Write techniques used for estimation of lidocain & phenobarbitone.

[6 marks]

Explain theories of dissolution.

[5 marks]

Write a note on ELISA.

[5 marks]

Write down TDM for Digoxin.

[6 marks]

Explain algorithm for interpretation of TDM result for drug used as prophylactic therapy.

[5 marks]

Write a note on first pass clearance.

[5 marks]

Bioavailability and Therapeutic Drug Monitoring — Winter 2019

Questions20

Related Papers